CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study
Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doi
Cancer Research and Treatment. 2018;50(2):398-404.   Published online 2017 May 10    DOI: https://doi.org/10.4143/crt.2017.074

Excel Download

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study
Cancer Research and Treatment. 2018;50(2):398-404   Crossref logo
Link1 Link2 Link3

Phase I Study of the Investigational Anti-Guanylyl Cyclase C (GCC) Antibody-Drug Conjugate (ADC) Mln0264 in Adult Patients with Advanced Gastrointestinal Malignancies Expressing GCC
Annals of Oncology. 2014;25:ii108   Crossref logo
Link1 Link2 Link3

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C
Investigational New Drugs. 2017;35(5):634-641   Crossref logo
Link1 Link2 Link3

Mln0264, an Investigational, First-In-Class Antibody-Drug Conjugate Targeting Guanylyl Cyclase C (Gcc): First-In-Human Study in Patients with Advanced Gastrointestinal Malignancies
Annals of Oncology. 2013;24:iv36   Crossref logo
Link1 Link2 Link3

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C
Investigational New Drugs. 2017;35(2):235-241   Crossref logo
Link1 Link2 Link3

Denosumab in Patients with Metastatic Prostate Cancer Previously Treated with Denosumab or Zoledronic Acid: 2-Year Open-Label Extension Phase Results from the Pivotal Phase 3 Study
Annals of Oncology. 2012;23:ix309   Crossref logo
Link1 Link2

Iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders: Results from a phase 3, randomized open-label study
SAGE Open Medicine. 2018;6:205031211878616   Crossref logo
Link1 Link2 Link3

EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)
Annals of Oncology. 2018;29:viii328   Crossref logo
Link1 Link2 Link3

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
Yearbook of Oncology. 2010;2010:26-27   Crossref logo
Link1 Link2

Photodynamic therapy of non-resectable cholangio carcinoma — A randomized prospective study — First results
Gastrointestinal Endoscopy. 2001;53(5):AB85   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.